Human recombinant DNA insulin-induced lipoatrophy in a patient with type 2 diabetes mellitus.
OBJECTIVE
To present the first case of lipoatrophy occurring in a patient with type 2 diabetes mellitus who was treated with human recombinant DNA (rDNA)-derived insulin as her only exposure to exogenous insulin.


METHODS
We describe the clinical findings in a 47-year-old woman with lipoatrophy after injection of human rDNA insulin for type 2 diabetes, and we review the related literature.


RESULTS
Although a few case reports have documented lipoatrophy in patients with type 1 diabetes treated with human insulin, to our knowledge no previous reports have described patients with type 2 diabetes in whom lipoatrophy developed after injection of human rDNA insulin. This was our patient's first exposure to exogenous insulin. No definite factor was found to be contributory to the development of lipoatrophy in this case, even though several factors may be related.


CONCLUSIONS
This is the first published case report of lipoatrophy occurring in a patient with type 2 diabetes mellitus who received human rDNA insulin as her only exposure to exogenous insulin.
Mu
L
L
Department of Medicine, Division of Endocrinology and Metabolism, The Brookdale University Hospital and Medical Center, Brooklyn, New York 11212, USA.
Goldman
J M
JM
D000273:Adipose Tissue / Q000473:pathology*; D001284:Atrophy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D011994:Recombinant Proteins